However, through the MDM2 inhibitor method, studies have found that p53 activation can effectively inhibit the proliferation of renal cancer cell lines14,39, which suggests that p53 could also has an essential role in kidney cancer, and new related signaling pathways may need to explore. Here, MDM2 is linked to renal carcinoma.